—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
LANCET NEUROLOGY《柳叶刀-神经病学》
月刊 - 英国
  • LANCET NEUROLOGY《柳叶刀-神经病学》
  • SCIE外文期刊
  • 期发文量27
  • 国人占比4.94%
  • 维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:1区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:1
    环比增速:0.00%
  • 期刊信息

  • 研究方向:医学-CLINICAL NEUROLOGY临床神经病学
  • 国际刊号:ISSN 1474-4422;EISSN 1474-4465
  • 期刊语言:英语
    出版地区:英国
  • 投稿网址:http://www.editorialmanager.com/thelancetneurology
  • 电子邮箱:e.becker-barroso@lancet.com (官网邮箱(170425更新))
  • 期刊官网:https://www.thelancet.com/journals/laneur/home
  • 作者指南:
  • 出版商网址:https://www.thelancet.com/
  • 出版地址:STE 800, 230 PARK AVE, NEW YORK, USA, NY, 10169
  • 期刊简介:LANCET NEUROLOGY《柳叶刀-神经病学》(月刊)。The Lancet Neurology publishes interesting and informative reviews on any topic connected with neurology, and considers any original research contribution that advocates change in, or illuminates, neurological clinical practice. Topics include, but are not limited to:Cerebrovascular disease;;Dementia/Alzheimer’s disease;Epilepsy and seizures;Genetics;Headache and migraine;Neurological infections;Motor neuron;disease/amyotrophic lateral sclerosis;Movement disorders;Multiple;sclerosis;Neuromuscular disorders;Peripheral nerve disorders;Paediatric neurology;Sleep disorders;Trauma;Neurological tumours.

  • 万维提示






  • 1、投稿方式:在线投稿。

    2、官网网址:https://www.thelancet.com/journals/laneur/home

    3、投稿网址:http://www.editorialmanager.com/thelancetneurology

    4、官网邮箱:editorial@lancet.com(编辑)

    e.becker-barroso@lancet.com(编辑)

    5、官网电话:+44 [0] 20 7424 4272(编辑)

    6、期刊刊期:月刊,一个月出版一期。

    2021427日星期二

                                

     

    投稿须知

    【官网信息】

     

    Information for Authors

    All Articles should, as relevant:

    Be up to 3500 words (4500 for randomised controlled trials) with 30 references (the word count is for the manuscript text only)

      Include an abstract (semistructured summary), with five paragraphs (Background, Methods, Findings, Interpretation, and Funding), not exceeding 300 words. Our electronic submission system will ask you to copy and paste this section at the “Submit Abstract” stage

    For randomised trials, the abstract should adhere to CONSORT extensions: abstracts (see Lancet 2008; 371: 281–83)

    When reporting Kaplan-Meier survival data, at each timepoint, authors must include numbers at risk, and are encouraged to include the number of censored patients.

    For intervention studies, the abstract should include the primary outcome expressed as the difference between groups with a confidence interval on that difference (absolute differences are more useful than relative ones). Secondary outcomes can be included as long as they are clearly marked as secondary and all such outcomes are reported

    Use the recommended international non-proprietary name (rINN) for drug names. Ensure that the dose, route, and frequency of administration of any drug you mention are correct

    Use gene names approved by the Human Gene Organisation.

    Novel gene sequences should be deposited in a public database  (GenBank, EMBL, or DDBJ), and the accession number provided.

    Authors of microarray papers should include in their submission the information recommended by the MIAME guidelines. Authors should also submit their experimental details to one of the publicly available databases:

    ArrayExpress or GEO

    Include any necessary additional data as part of your EM submission

    All accepted Articles should include a link to the full study

    protocol published on the authors’ institutional website  (see Lancet 2009; 373: 992 and Lancet 2010; 375: 348)

    We encourage researchers to enrol women and ethnic groups

    into clinical trials of all phases, and to plan to analyse data by sex and by race

    For all study types, we encourage correct use of the terms sex  (when reporting biological factors) and gender (when reporting identity, psychosocial, or cultural factors). Where possible, report the sex and/or gender of study participants, and describe the methods used to determine sex and gender.

    Separate reporting of data by demographic variables, such as age and sex, facilitates pooling of data for subgroups across studies and should be routine, unless inappropriate. Discuss the influence or association of variables, such as sex and/or gender, on your findings, where appropriate, and the limitations of the data.

    ……






欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码